Literature DB >> 25305205

Presence of calreticulin mutations in JAK2-negative polycythemia vera.

Julien Broséus1, Ji-Hye Park2, Serge Carillo3, Sylvie Hermouet4, François Girodon5.   

Abstract

Calreticulin (CALR) mutations have been reported in Janus kinase 2 (JAK2)- and myeloproliferative leukemia (MPL)-negative essential thrombocythemia and primary myelofibrosis. In contrast, no CALR mutations have ever been reported in the context of polycythemia vera (PV). Here, we describe 2 JAK2(V617F)-JAK2(exon12)-negative PV patients who presented with a CALR mutation in peripheral granulocytes at the time of diagnosis. In both cases, the CALR mutation was a 52-bp deletion. Single burst-forming units-erythroid (BFU-E) from 1 patient were grown in vitro and genotyped: the same CALR del 52-bp mutation was noted in 31 of the 37 colonies examined; 30 of 31 BFU-E were heterozygous for CALR del 52 bp, and 1 of 31 BFU-E was homozygous for CALR del 52 bp. In summary, although unknown mutations leading to PV cannot be ruled out, our results suggest that CALR mutations can be associated with JAK2-negative PV.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25305205     DOI: 10.1182/blood-2014-06-583161

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 3.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

4.  Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Authors:  Julie Mondet; Ji-Hye Park; Audrey Menard; Christophe Marzac; Serge Carillo; Emmanuel Pourcelot; Francois Girodon; Xenia Cabagnols; Laurence Lodé; Nuria Socoro; Martine Chauvet; Claude-Eric Bulabois; Pascale Cony-Makhoul; Selim Corm; Jean-Yves Cahn; Pascal Mossuz
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

5.  Absence of CALR mutations in JAK2-negative polycythemia.

Authors:  Aurélie Chauveau; Olivier Nibourel; Sylvie Tondeur; Damien Luque Paz; Olivier Mansier; Franciane Paul; Mathieu Wemeau; Claude Preudhomme; Eric Lippert; Valérie Ugo
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 6.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.

Authors:  Belinda B Guo; Richard J Allcock; Bob Mirzai; Jacques A Malherbe; Fizzah A Choudry; Mattia Frontini; Hun Chuah; James Liang; Simon E Kavanagh; Rebecca Howman; Willem H Ouwehand; Kathryn A Fuller; Wendy N Erber
Journal:  Am J Pathol       Date:  2017-05-11       Impact factor: 4.307

Review 8.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

Review 9.  Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Authors:  Alain Antoine Mina; Brady Stein
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 10.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.